Efficacy of intravitreal conbercept injection in the treatment of retinopathy of prematurity

Bai, Yichen; Nie, Huanjie; Wei, Shengcai; Lu, Xiaoyan; Ke, Xiaoyan; Ouyang, Xuejun; Feng, Songfu

doi:10.1136/bjophthalmol-2017-311662

Cited by 35 publications

(35 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our previous studies 6,7 of conbercept demonstrated similar ROP recurrence rates (6/38 and 3/20, respectively), which were consistent with a study from another team in South China (8/48). 8 In our comparative study, 7 the recurrence rate was lower with conbercept than with ranibizumab (15/28, 53.6%). Our previous study found a similar recurrence rate (45.45%) of ranibizumab.…”

Section: Discussionmentioning

confidence: 62%

“…A few studies have indicated that intravitreal anti-VEGF drugs induce systemic VEGF suppression for weeks to months [3][4][5] , although no significant adverse events have been reported to date. There have been occasional reports on the use of conbercept, a novel anti-VEGF agent, for ROP treatment [6][7][8] , however, the effect of conbercept on systemic VEGF concentrations in ROP has not yet been reported.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Serum levels of cytokines in infants treated with conbercept for retinopathy of prematurity

Cheng

Zhu

Linghu

et al. 2020

Sci Rep

View full text Add to dashboard Cite

intravitreal anti-vascular endothelial growth factor (VeGf) agents have revolutionized the treatment of retinopathy of prematurity (ROP); however, there are concerns regarding the potential systemic complications caused by those treatments. this study aimed to determine the serum concentrations of cytokines in infants with Rop and to evaluate the changes in serum VeGf concentrations after intravitreal conbercept (IVC). Sixty infants with ROP treated with IVC 0.25 mg were included. Blood samples were collected before treatment as well as 1 week and 4 weeks after treatment. Serum levels of 45 types of cytokines were measured by a multiplex bead assay. We observed that IVC 0.25 mg in ROP patients suppressed the circulating levels of VEGF-A and VEGF-D as of 1 week after injection, and these growth factor levels returned to baseline at 4 weeks. No significant differences were observed in the serum levels of the other cytokines between baseline and 1 or 4 weeks after IVC.

show abstract

Section: Discussionmentioning

confidence: 62%

mentioning

confidence: 99%

Serum levels of cytokines in infants treated with conbercept for retinopathy of prematurity

Cheng

Zhu

Linghu

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“…7,[30][31][32] In addition, it was shown to have a favorable outcome effect for ROP, although well-designed clinical trials have yet to be conducted. 33,34 Given its reproducibility and consistency, the laserinduced CNV mouse or rat model has been used in the preclinical testing of biological agents for the neovascular AMD pathology. 35,36 In the present in vivo suppression study of choroidal neovascularization, VEGF-Grab showed efficacy comparable to that of aflibercept.…”

Section: Discussionmentioning

confidence: 99%

Preclinical Efficacy and Safety of VEGF-Grab, a Novel Anti-VEGF Drug, and Its Comparison to Aflibercept

Hong

Park

Kim

et al. 2020

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

“…It has been proven to be helpful in managing different retinal neovascular diseases. [22][23][24] Literatures revealed the success of Anti-VEGF agents in treating CNV secondary to choroidal osteomas, in particular the use of Aflibercept in non-responder to bevacizumab and ranibizumab. Considering the similarity in pharmacological characteristics between Conbercept and Aflibercept, we decided to give Conbercept injection intravitreally to our case-a young female with CNV secondary to unilateral choroidal osteomas.…”

Section: Discussionmentioning

confidence: 99%

Case report:Intravitreal Conbercept for treatment of choroidal neovascularisation secondary to choriodal osteoma

M¹,

y²

2019

Preprint

View full text Add to dashboard Cite

Background: Choriodal osteoma is a rare condition. Although anti-VEGF treatment has been reported to be effective in managing choroidal neovascularisation secondary to choriodal osteoma, to the best of our knowledge, this is the first report of using conbercept in such condition. Case presentation:This report describes a case of choroidal neovascularisation secondary to choriodal osteoma. A 37-year old female presented with decreased vision and distortion in left eye. Fundus image revealed an orange-yellow lesion with clear boundary in the macular area. Fluorescein angiography indicated choroidal neovascularization(CNV). OCT, B-scan and CT scan showed features of choroidal osteoma. Intravitreal Conbercept was given for four times over a period of 10 months, resulting stability of visual acuity and regression of CNV. Conclusions:Intravitreal Conbercept can be an effective modality in short term in controlling choroidal neovascularisation secondary to choriodal osteoma.

show abstract

Efficacy of intravitreal conbercept injection in the treatment of retinopathy of prematurity

Abstract: IVC injection is an effective treatment for ROP.

Cited by 35 publications

References 41 publications

Serum levels of cytokines in infants treated with conbercept for retinopathy of prematurity

Serum levels of cytokines in infants treated with conbercept for retinopathy of prematurity

Preclinical Efficacy and Safety of VEGF-Grab, a Novel Anti-VEGF Drug, and Its Comparison to Aflibercept

Case report:Intravitreal Conbercept for treatment of choroidal neovascularisation secondary to choriodal osteoma

Contact Info

Product

Resources

About